This study looks at the safety and effectiveness of a medicine called amlitelimab for people aged 12 and older with moderate to severe atopic dermatitis (AD). AD, also known as eczema, is a skin condition causing itchy, inflamed skin. This study lasts up to 180 weeks, which includes a screening period of 2-4 weeks, treatment for up to 160 weeks, and a follow-up period of 20 weeks.

During the study, participants will visit the clinic 26 times. To join, participants must have had AD for at least a year and tried other treatments without success. They should be willing to follow study procedures and cannot be pregnant or breastfeeding. Some conditions may exclude participation, like certain infections, previous organ transplants, or specific allergies.

• Study Duration: Up to 180 weeks, with 26 clinic visits.
• Eligibility: Ages 12+, with moderate to severe AD and poor response to prior treatments.
• Exclusions: Includes specific medical conditions and recent live vaccinations.